Myelin-associated glycoprotein gene mutation causes Pelizaeus-Merzbacher disease-like disorder by Lossos, Alexander et al.
Myelin-associated glycoprotein gene
mutation causes Pelizaeus-Merzbacher
disease-like disorder
Alexander Lossos,1,* Nimrod Elazar,2,* Israela Lerer,3,* Ora Schueler-Furman,4
Yakov Fellig,5 Benjamin Glick,6 Bat-El Zimmerman,3 Haim Azulay,5 Shlomo Dotan,7
Sharon Goldberg,7 John M. Gomori,8 Penina Ponger,1 J. P. Newman,1 Hodaifah Marreed,3
Andreas J. Steck,9 Nicole Schaeren-Wiemers,9 Nofar Mor,2 Michal Harel,10 Tamar Geiger,10
Yael Eshed-Eisenbach,2 Vardiella Meiner3,* and Elior Peles2
*These authors contributed equally to this work.
Pelizaeus-Merzbacher disease is an X-linked hypomyelinating leukodystrophy caused by mutations or rearrangements in PLP1. It
presents in infancy with nystagmus, jerky head movements, hypotonia and developmental delay evolving into spastic tetraplegia
with optic atrophy and variable movement disorders. A clinically similar phenotype caused by recessive mutations in GJC2 is
known as Pelizaeus-Merzbacher-like disease. Both genes encode proteins associated with myelin. We describe three siblings of a
consanguineous family manifesting the typical infantile-onset Pelizaeus-Merzbacher disease-like phenotype slowly evolving into a
form of complicated hereditary spastic paraplegia with mental retardation, dysarthria, optic atrophy and peripheral neuropathy in
adulthood. Magnetic resonance imaging and spectroscopy were consistent with a demyelinating leukodystrophy. Using genetic
linkage and exome sequencing, we identiﬁed a homozygous missense c.399C4G; p.S133R mutation in MAG. This gene, previ-
ously associated with hereditary spastic paraplegia, encodes myelin-associated glycoprotein, which is involved in myelin mainten-
ance and glia-axon interaction. This mutation is predicted to destabilize the protein and affect its tertiary structure. Examination of
the sural nerve biopsy sample obtained in childhood in the oldest sibling revealed complete absence of myelin-associated glyco-
protein accompanied by ill-formed onion-bulb structures and a relatively thin myelin sheath of the affected axons.
Immunoﬂuorescence, cell surface labelling, biochemical analysis and mass spectrometry-based proteomics studies in a variety of
cell types demonstrated a devastating effect of the mutation on post-translational processing, steady state expression and sub-
cellular localization of myelin-associated glycoprotein. In contrast to the wild-type protein, the p.S133R mutant was retained in the
endoplasmic reticulum and was subjected to endoplasmic reticulum-associated protein degradation by the proteasome. Our ﬁnd-
ings identify involvement of myelin-associated glycoprotein in this family with a disorder affecting the central and peripheral
nervous system, and suggest that loss of the protein function is responsible for the unique clinical phenotype.
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Introduction
Pelizaeus-Merzbacher disease (PMD; OMIM #312080) is
the prototype hypomyelinating leukodystrophy (HLD1) clas-
sically presenting in infancy with nystagmus, jerky head
movements, hypotonia and developmental delay evolving
into spastic tetraplegia with optic atrophy and variable
movement disorders (Hobson and Garbern, 2012). It is an
X-linked disorder caused by mutations or rearrangements in
the PLP1 gene encoding two alternatively spliced isoforms of
an integral membrane proteolipid protein (PLP/DM20), a
major component of the CNS and a minor one of the per-
ipheral nervous system (PNS) compact myelin (Han et al.,
2013). A clinically similar phenotype associated with hypo-
myelination but not linked to PLP1 is termed Pelizaeus-
Merzbacher-like disease (PMLD) (Hobson and Garbern,
2012) and classiﬁed with a genetically heterogeneous group
of HLD (Pouwels et al., 2014). PMLD1 (OMIM #608804),
classiﬁed as HLD2, accounts for 8% of such patients
(Henneke et al., 2008). It is caused by recessive mutations
in GJC2, encoding gap junction protein gamma 2 or con-
nexin 47 expressed in oligodendrocytes and involved in
oligodendrocyte-astrocyte channelling and in the mainten-
ance of myelin (Orthmann-Murphy et al., 2009).
Additional disorders resembling PMD are associated with
delayed myelination, as in SLC16A2-related dysfunction of
monocarboxylate thyroid hormone transporter 8 (Vaurs-
Barriere et al., 2009) (OMIM #300523), or with hypomye-
lination secondary to a neuronal or axonal process, as in a
presumed AIMP1-related dysregulation of the neuroﬁla-
ment network in HLD3 (Feinstein et al., 2010; Pouwels
et al., 2014) (OMIM #260600), in HSPD1-related
compromise of the mitochondrial chaperonin HSP60 in
HLD4 (Magen et al., 2008; Pouwels et al., 2014)
(OMIM #612233), and occasionally in TUBB4A-related
tubulin beta-4A dysfunction in HLD6 (Miyatake et al.,
2014; Shimojima et al., 2015) (OMIM #612438).
We report the clinical, molecular and cell biological data
of a multiplex family with early PMD-like disorder slowly
evolving into a form of hereditary spastic paraplegia (HSP)
associated with demyelination due to a homozygous loss-
of-function mutation in MAG, the gene previously reported
in HSP (Novarino et al., 2014). Encoded protein, known as
myelin-associated glycoprotein MAG, is a cell adhesion
molecule that belongs to the immunoglobulin (Ig) super-
family of proteins enriched in myelinating glial cells and
involved in glia-axon interactions.
Materials and methods
Patients
Since 2009, we have evaluated three affected siblings of a con-
sanguineous family of Palestinian Arab origin (Fig. 1A). Of the
living clinically unaffected family members, 13 were available
for examination. The family was registered in the Israeli
HSP Database in 2009. Clinical diagnosis and a prospective
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Figure 1 Homozygous c.399C`G mutation in MAG in the autosomal recessive PMD-like disorder. (A) Pedigree of the family.
Circles represent females and squares males. Filled symbols indicate affected individuals and double lines consanguinity by descent. (B) DNA
sequencing identified a c.399C4G, p.S133R mutation in MAG. Upper panel shows wild-type sequence (WT) and lower panel shows affected
homozygous Patient III-2. (C) Restriction-based analysis of individuals from the extended family. PCR products were digested with AvaII resulting
in a wild-type (183 + 65 bp) and a mutant allele (141 + 65 + 42 bp). M = marker; UC = uncut; HTZ = heterozygote; HMZ = homozygote, with
the letters designating position in the pedigree. (D) Modelling of the p.S133R mutation effect on MAG stability and structure. Structural model of
the first Ig-like domain (residues 22–139) suggests that S133 points into the core of this domain to form hydrogen bonds with a neighbouring
proline residue. Mutation to arginine will create strong clashes leading to unfolding and destabilization of the protein. (I) Overall model of the first
Ig-like domain of MAG. S133 (in red) is located in the c-terminal strand of the first Ig-like domain (in green), adjacent to the n-terminal strand of
this (in blue). Interaction between these two strands holds the domain together. (II) Close-up of the S133 position (green central residue in sticks
representation) and its surrounding showing a potential hydrogen bond formed with a neighboring backbone, P27 at the N-terminal of the Ig-like
domain (dashed lines). (III) Mutation of serine to arginine (in white) at position 133 leads to strong clashes (in red) and may cause opening of the
sheet to its unfolding and misfolding. (E) Representative imaging findings. Cerebral MRI in Patient III-2 at age 7 (I) and 25 (II–V and VII) years and
in Patient III-3 at age 24 (VI) showing mild progressive atrophy of the optic chiasm, corpus callosum and cerebellum on T1-weighted images (I and
II), a periventricular rim of the cerebral white matter hyperintensity on FLAIR (III) and T2-weighted (IV) images, which appears hypointense on
T1( + Gd)-weighted images (V, arrow), and scattered foci of hyperintensity on FLAIR-weighted images (VI). Areas of the unaffected cerebral white
matter appear of a normal signal. (VII) Cerebral 1H-magnetic resonance spectroscopy (echo time 135) spectrum at the centrum semiovale
showing an increase in choline peak.
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follow-up were performed using the clinical chart (http://
spatax.wordpress.com/downloads/) developed by the interna-
tional SPATAX (spastic paraplegia and ataxia) network (co-
ordinator: A. Durr, MD, PhD). For cognitive evaluation and
assessment of the intelligence quotient we used Mini-Mental
State Examination (Folstein et al., 1975) and the Test for Non-
Verbal Intelligence (TONI-2), a language-free tool for obtain-
ing predicted non-verbal intelligence scores (www.agsnet.com/).
The study was approved by the institutional and national review
boards. Informed consent was obtained prior to enrolment from
all the participants.
Autozygosity mapping and
linkage analysis
Because of the parental consanguinity, we determined shared
homozygous regions using genome-wide linkage analysis with
the Affymetrix Gene-Chip Human Mapping 250K Nsp Array.
Data handling, evaluation and the statistical analysis were per-
formed using HomozygosityMapper (Seelow et al., 2009). To
assess and conﬁrm segregation with the phenotype, we used se-
lected short tandem repeat (STR) markers for genotyping the
remaining family members (details available upon request).
Whole exome sequencing
For whole exome sequencing, DNA obtained from Patient III-2
was fragmented, end paired, adenylated and ligated to adap-
ters. Exome capture and sequencing was performed with the
Agilent SureSelect 38Mb All Exon Hybridization Array. The
SureSelect protocol was used to prepare libraries for paired-
end sequencing on an Illumina HiSeq 2000 platform with
mean depth coverage of 30 . The sequenced reads were
aligned, and variant calling was performed with the October
2011 release of DNAnexus software with the human genome
assembly hg19 (GRCh37) as reference. The raw list of variants
was ﬁltered to exclude variants present in the dbSNP129, in
the ‘HapMap’ and in the ‘1000 Genomes’ databases. Rigorous
ﬁltering based on global (minor allele frequency) MAF 5 1%,
predicted functional consequence, and sequence conservation
left us with sequence variants of interest that were validated
and veriﬁed using Sanger sequencing and restriction fragment
length polymorphism (RFLP) analysis.
Mutation analysis
For the MAG c.399C4G; p.S133R mutation (NM_002361.3),
PCR product (248bp; ampliﬁed by forward 5’-GAAACTGC
ACCCTCCTGCT-3’ and reverse 5’-CAAATCAGCACCTCCC
AGATC-3’) was digested with AvaII (Promega) as per manufac-
turer’s protocol and run on NuSieve agarose (3:1%) gel lead-
ing to the detection of a normal and a mutant allele
(183 + 65bp and 141 + 65 + 42bp, respectively).
For the PLP1 c.594C4A variant (NM_000533.3), we used
AlwNI restriction enzyme analysis with the primers
PLP1EX5F-5’-TGGTTTTAATGTCTGGCACA-3’ and PLP1
EX5R-5’-CTCATAATCACCACCCTCCTT-3’. PLP1 cDNA
was analysed with the primers PLP1-290F-5’-AGGCAGATC
TTTGGCGACTA-3’ and PLP1-800R-5’-GTGAGCAGGGA
AACCAGTGT-3’. PCR products were run on agarose gel
and visualized under UV illumination.
Expression of wild-type and
mutant MAG
Human MAG was cloned by reverse transcription-PCR from
total RNA of human femoralis cDNA and was subcloned into
pb-actin-ECGFP exchanging the ECGFP sequence (pb-actin-
hSMAG), or into the same vector upstream of the EGFP
(pb-actin-hSMAG-GFP) (Erb et al., 2003). c.399C4G muta-
tion was generated by PCR on pb-actin-hSMAG as template.
A forward primer (5’-CTCCATCTCCAGCCTCGGG-3’) and a
reverse primer (5’-GGTGTTGACGATATCCAGGACCCTGT
GCTCTGAGAAGGTGTAC-3’) containing the mutation and
a neighbouring endogenous EcoRV site were used. A
HindIII–EcoRV-digested PCR fragment was ligated into the
template plasmid in the same site to generate pb-actin-
hSMAG-S133R. The pb-actin-hSMAG-S133R-GFP was
generated by replacing the HindIII–EcoRV fragment of
hSMAG-GFP with the one obtained from pb-actin-hSMAG-
S133R. Plasmids containing myc-tagged versions of wild-type
and mutant MAG were made by PCR cloning of the corres-
ponding genes into pMX vector (Addgene). The latter plasmid
was also used to generate viral vectors containing GFP-tagged
proteins. The open reading frame of all constructs was con-
ﬁrmed by DNA sequencing. Transfection of HEK-293T, COS7
and Schwann cells were done using CaPO4, Lipofectamine
TM
(Invitrogen), and LipofectamineTM 2000 reagent (Invitrogen),
respectively. Lentiviral stocks were generated by CaPO4-
transfection of phoenix packaging cells (Invitrogen). Rat
Schwann cells and oligodendrocyte precursor cells were cul-
tured as described (Eshed et al., 2005).
Antibodies and immunofluorescence
labelling
We used mouse monoclonal antibody (MAb) D3A2G5 against
the extracellular domain of human MAG (Burger et al., 1990),
a monoclonal anti-mouse MAG (clone MAb 513, EMD
Millipore), rabbit polyclonal anti-MAG (H-300; Santa Cruz
Biotechnologies), and polyclonal anti-L-MAG (Heape et al.,
1999, kindly obtained from Dr A. Heape, University of
Oulu, Finland). For immunohistochemical staining of the
sural nerve sample, we used anti-MAG antibody against
amino acids 1–300 mapping near the N-terminus of human
MAG (H-300); sc-15324, Santa Cruz Biotechnology Inc, 1:50,
and NF-Neuroﬁlament Protein, Clone 2F11, Dako, 1:500.
Other antibodies included mouse anti-calnexin (MAb3126;
EMD Millipore), mouse monoclonal antibody to vesicle dock-
ing protein p115 (kindly provided by Dr S. Lev, Weizmann
Institute, Israel), rabbit anti-VapB (K-16; Santa Cruz
Biotechnologies), and rabbit polyclonal antibody to Caspr
(Peles et al., 1997). Fluorophore-coupled secondary antibodies
included 488- coupled anti-rabbit and mouse IgG (Invitrogen),
Cy3-coupled anti-rabbit and anti-mouse (Jackson
Laboratories). Immunoﬂuorescence labelling was carried out
essentially as described (Spiegel et al., 2007). Fluorescence
images were obtained using an Axioskop2 microscope
equipped with an ApoTom imaging system (Carl Zeiss) ﬁtted
with a Hamamatsu ORCA-ER CCD camera. Images were
acquired and processed using the Zen2012 (Carl Zeiss) and
Photoshop software (Adobe).
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Structural protein modelling
Structural model of MAG and the corresponding MAG-S133R
mutant was generated using the HHpred tool (So¨ding, 2005),
to identify structural templates for homology modelling, and
the I-Tasser tool (Roy et al., 2010), to create the model using a
longer domain deﬁnition than predicted earlier by other tools
(May et al., 1998). The structure of a similar protein siaload-
hesin (Protein Data Bank code 1qfo) with a 26% sequence
identity and 66% sequence similarity (May et al., 1998)
served as the basis for this model.
Immunoprecipitation and western
blot analysis
Immunoprecipitation, sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) and western blotting were
done as described (Spiegel et al., 2007) with the exception
that the chemiluminescence signal was detected using the
ChemiDoc MP System (Bio-Rad). Deglycosylation and remov-
ing of high mannose structures was achieved by incubating the
denatured immunocomplexes with endoglycosidase H (New
England Biolabs) for 1 h at 37C. Co-immunoprecipitation of
endogenously expressed proteins was performed using HEK-
293T cells either incubated with dimethyl sulphoxide or incu-
bated with the indicated amount of bortezomib overnight.
Cells were solubilized in TritonTM X-100 containing buffer,
incubated with GFP-Trap-Agarose (ChromoTek) followed
by western blot analysis (Peles et al., 1997). When indicated,
protein synthesis was stopped by the addition of cyclohexa-
mide to a ﬁnal concentration of 50 mg/ml for various times.
Cells were then washed in phosphate-buffered saline, lysed
and total protein lysates were subjected to western blot ana-
lysis. Cell surface biotinylation was done as described (Gollan
et al., 2003).
Proteomics sample preparation
and mass spectrometry analysis
Cells were lysed with 1% NP40, 150mM NaCl in 50mM Tris
HCl pH 7.6 buffer supplemented with protease inhibitors.
Protein from each sample (5mg) was mixed with GFP-
Trap-Agarose (ChromoTek) for 2 h at 4C. Samples were
washed three times with the same buffer containing 0.05%
NP40 followed by three washes without NP40. Proteins
were reduced with 1mM dithiothreitol in 2M urea and sub-
sequently alkylated with 5 mM iodoacetamide. On-bead pro-
tein digestion was performed with sequencing grade-modiﬁed
trypsin (Promega) and peptides were acidiﬁed with triﬂuoroa-
cetic acid (TFA) followed by puriﬁcation on C18 (stageTips).
Liquid chromatography-mass spectrometry (LC-MS/MS) ana-
lysis was performed on the EASY-nLC1000 UHPLC system
(Thermo Scientiﬁc) coupled to the Q-Exactive Plus mass spec-
trometers (Thermo Scientiﬁc) via the EASY-SprayTM ionization
source. Peptides were loaded onto 50 cm long EASY-SprayTM
PepMap columns (Thermo Scientiﬁc) with 140-min gradient
using buffer A (0.1% formic acid) and separated using a 7–
28% buffer B (80% acetonitrile, 0.1% formic acid). All mass
spectrometry measurements were done in a data-dependent
mode using a top-10 method. Raw mass spectrometry ﬁles
were analysed with MaxQuant version 1.5.0.36 and the
Andromeda search engine integrated into the same version
(Cox et al., 2011). MS/MS spectra were searched against the
UniprotKB database. Quantiﬁcation was performed using the
label-free algorithm MaxLFQ (Cox et al., 2014).
All bioinformatics analyses were performed on log2 LFQ
intensity values. Data analysis was performed after ﬁltering
for valid values in at least two samples in one group (empty
vector/wild-type/S133R mutant). Statistical tests and calcula-
tions were done using the Perseus program. To identify poten-
tial interactors, Student’s t-test was performed between empty
vector triplicate and either wild-type or mutant triplicates with
permutation-based false discovery rate (FDR) 50.05 and
S0 = 1.5 and resulted in a list of 1010 proteins with higher
intensities in the MAG samples. A second Student’s t-test
(FDR = 0.05, S0 = 1.5) was performed on these proteins to dis-
tinguish between the wild-type and mutant binders.
Hierarchical clustering was done after z-score normalization
of the proteins, and was based on Euclidean distances between
averages. Protein networks were constructed in the string data-
base and visualized in Cytoscape. Fisher exact tests were done
with a Benjamini–Hochberg FDR threshold of 0.02.
Results
Patients manifest complicated
hereditary spastic paraplegia
The main clinical ﬁndings at initial examination and the
available documented medical history are summarized in
Table 1. In short, the patients were born after uneventful
pregnancies and labour and, except for Patient III-2 who
had transverse limb defect affecting phalanges in three ﬁn-
gers of his right hand, none had dysmorphic features. Head
circumferences were within normal limits. Early develop-
mental and speech delay were noticed soon after birth
with initiation of supported gait at age 4–5 years and
slow but progressive deterioration to walker and wheel-
chair over a period of 15 years, despite physiotherapy.
Borderline-to-mild mental retardation was documented in
all three siblings. They attended special school, obtained
basic reading and writing skills, and achieved partial inde-
pendence in basic daily activities. Based on the combination
of early ocular and neurological ﬁndings (Table 1), initial
diagnosis of PMD was raised by age 5 years (B.G.).
On examination, patients had spastic dysarthria and
moderate-to-severe spastic paraparesis with hyporeﬂexia
in the arms and knees, reduced (Patient III-5) or absent
(Patients III-2 and III-3) ankle reﬂexes and bilateral exten-
sor plantar response. Muscle tone in the arms was only
mildly increased and was associated with dysmetria.
Reduced deep tendon reﬂexes together with distal leg atro-
phy and distal vibration sensory loss suggested an asso-
ciated peripheral neuropathy. Patients displayed mild
psychomotor slowing, intact short-term verbal memory,
full orientation in all domains, and scored in the range of
mild (Patient III-5) to borderline (Patients III-2 and III-3)
mental retardation.
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Formal neuro-ophthalmological examination (Table 1)
revealed similar ﬁndings in all three siblings, including hori-
zontal nystagmus and optic nerve atrophy with reduced
visual acuity, visual ﬁeld defect, and thinning of the peri-
papillary retinal ganglion cell ﬁbres (Supplementary
Table 1). In addition, all had hypermetropia and astigma-
tism, and Patient III-2 had primary open angle glaucoma
well-controlled with locally applied medications. Recorded
visual-evoked potentials were of signiﬁcantly low amplitude
and of prolonged latency, more in the older siblings
(Supplementary Table 1). Brainstem auditory-evoked re-
sponses were of delayed latency but a recognizable wave
pattern in all three siblings.
Over a period of 4 years, all three siblings were available
for follow-up examinations, showing a very slow progres-
sion of their functional motor disability and of the clinical
ﬁndings.
Metabolic screening and EEG were normal in Patient III-2.
Peripheral nerve conduction study (Supplementary Table 1)
demonstrated in the elder siblings, prolonged distal motor
latencies with normal or borderline compound motor
action potentials and reduced motor and sensory velocities,
indicating motor and sensory peripheral neuropathy. There
were no temporal dispersion or conduction blocks.
Cerebral MRI (Supplementary Table 1) demonstrated bi-
lateral optic nerve atrophy accompanied by mild corpus
callosum and cerebellar atrophy. In addition, there was a
rim of predominantly posterior cerebral periventricular and
subtle pontine white matter T2/FLAIR-hyperintensity, and
rare scattered foci of subcortical white matter hyperinten-
sity (Fig. 1E). Areas of unaffected cerebral white matter
appeared of a normal signal, suggesting a normal myelin-
ation pattern. Mild ventricular dilatation was also noted,
likely the result of white matter volume loss. Although
these ﬁndings were similar in all three siblings, they
tended to be more pronounced in the older ones.
Furthermore, comparison with a study from 18 years ear-
lier in Patient III-2 revealed slow progression of all ﬁndings.
Single volume 1H-magnetic resonance spectroscopy ob-
tained with PRESS acquisition at the centrum semiovale
(Fig. 1E) revealed elevated ratios of choline to creatine
and to N-acetyl aspartate at a long (135ms) echo time,
Table 1 Clinical findings at the initial evaluation of the siblings with a homozygous c.399C4G mutation in MAG
Patient III-2 III-3 III-5
Sex Male Male Female
Age at: (years)
Initial evaluation 23 22 17
Current 28 26 21
Age at documented finding (years)
Nystagmus Days 1 1
Head nodding 1 – –
Hypotonia Days 1 1
Hypo-areflexia 4 1 4
Spasticity 4 9 9
Pyramidal signs 4 9 4
Developmental delay + + +
Supported walking 5 4 5
Walking with walker 10 9 9
Wheelchair-bound 20 19 –
Cognitive
MMSE 25/30 23/30 24/30
IQ 71 76 61
Ocular right/left
Visual acuity 0.1/FC 0.2/0.2 0.16/0.16
Refraction Hypermetropia, astigmatism Hypermetropia, astigmatisms High hypermetropia, astigmatism
IOP (normal 521 mm Hg) 31/32 10/10 10/10
RAPD R – –
Oculomotor Nystagmus Nystagmus Nystagmus
Optic nerve Pale excavation/central pale excavation Temporal pallor/temporal pallor Temporal pallor/temporal pallor
Spastic dysarthria Moderate Moderate Mild
Spastic paraparesis (severity) Severe Severe Moderate
Hypo-areflexia + + +
Extensor plantar response, right/left + / + + / + + / +
Dysmetria Mild Mild Mild
Distal sensory deficit Vibration Vibration Vibration
Distal leg atrophy + + +
MMSE = Mini-Mental State Examination; R = right; L = left; FC = finger counting; IOP = intraocular pressure; RAPD = relative afferent papillary defect.
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particularly in the older siblings (Supplementary Table 1).
Taken together, these ﬁndings were consistent with a
slowly progressive leukodystrophy of a demyelinating
rather than a hypomyelinating pattern (Bizzi et al., 2008).
At age 9 years, Patient III-2 was evaluated elsewhere. Left
sural nerve biopsy performed at that time was interpreted
as normal. Revision of parafﬁn embedded sections, epoxy
resin embedded semi-thin sections and electron microscopy
(Fig. 2) did not reveal signiﬁcant alterations, except for rare
ill-formed onion-bulb structures and apparent minimal loss
of axon-glia interaction in rare myelinated axons, although
traction or tearing artefact cannot not be excluded. There
was no ‘wide-spaced’ myelin formation and no apparent
decrease in axonal density. Although subtle, these features
may indicate minimal demyelination.
Molecular analysis identifies
c.399C4G; p.S133R mutation inMAG
Autozygosity mapping in Patients III-2 and III-3 (Fig. 1A)
yielded four shared homozygous regions encompassing
the following chromosomal regions: chr11:47993662–
50299865, chr11:50300221–56027727, chr19:13552763–
35976171, and chr18: 45 667 057–67599516 (build
hg19). To narrow these candidate regions, we performed
segregation analysis using polymorphic microsatellites cor-
responding to these shared loci, which ruled out chromo-
some 18 and chromosome 11 regions as potential
candidate options. We remained with a single 21Mb
homozygous region corresponding to chromosome 19
(15244658–35976171) encompassing 234 protein-coding
genes and a total of 1350 exons.
In light of this large number of genes, we elected to per-
form whole exome sequencing in Patient III-2. The number
of called variants [insertion/deletions (Indels) and single
nucleotide variations (SNVs)] was 108357. Of these vari-
ants, 878 were homozygous located in the linked non-
excluded region on chromosome 19. Filtering this group re-
sulted in 190 coding variants that were all common and
frequently found in the published and in-house variant data-
bases (EVS, 1000 genomes, HapMap) except for a unique
variant in the MAG gene on chromosome 19:35786868. A
silent variant rs2301600 in this codon is a common SNP;
however, affected individuals in this family carried a mis-
sense change c.399C4G, p.S133R (Fig. 1B). In silico ana-
lyses with several pathogenicity prediction programs
predicted the amino acid substitution to be tolerated by
SIFT yet damaging to the protein function using PolyPhen-
2 and MutationTaster. Restriction-based analysis demon-
strated perfect segregation in the extended family and only
the three patients were homozygotes for the mutation (Fig.
1C). This variant was never reported in the database gener-
ated by the Exome Aggregation Consortium (ExAC),
Cambridge, MA (http://exac.broadinstitute.org) (December,
2014). Serine at position 133 is moderately conserved all
the way down to the zebraﬁsh in which a similar polar
neutral amino acid is found. Screening 192 anonymous
chromosomes from a similar ethnic background did not
reveal any carrier for the mutation.
Because of a PMD-like phenotype, we extensively
searched for potential variants in the PLP1 gene. A single
variant on chromosome X, 103 042867 predicted to cause
a silent change (c.594C4A; p.Gly198Gly), was further
analysed to assess potential splicing effect. This variant
did not segregate with the phenotype and, although
shared by the two affected brothers Patients III-2 and
III-3, was not detected in their affected sister, Patient
III-5. Furthermore, PLP1 cDNA did not differ in size be-
tween the three patients and normal controls, and we con-
cluded that the disease phenotype is not inﬂuenced by this
variant. We did not identify potential disease-causing vari-
ants in the HLD-causing genes AIMP1, GJC2, HSPD1,
TUBB4A, FAM126A and RARS.
p.S133R mutation is predicted
to affect the structure of MAG
The p.S133R is located at the end of the ﬁrst of ﬁve Ig-like
domains (Letunic et al., 2012). To evaluate the structural
importance of the affected S133 residue, we generated a
structural model of 118 residues (22–139) showing that
S133 points into the protein core to form hydrogen
bonds with the backbone of residues at the beginning of
the Ig-like domain (Fig. 1D). This interaction is also
observed in the solved homologue structures and could ex-
plain the rather unusual burial of a polar residue in the
core. Position 133 is located within the last strand of the
Ig-like domain and is inserted between two additional
strands to form a beta-sheet, including a bulge of different
sizes just prior to 133 (Fig. 1D).
The p.S133R mutation results in the replacement of a
small serine with a much larger arginine, thereby disrupting
this domain and leading to a signiﬁcant destabilization of
the protein (Fig. 1D). In addition, this mutation could also
affect glycosylation, as it is located in the vicinity of the
R118, a sialic acid binding site in the same domain.
p.S133R mutation affects the
post-translational processing
and folding of MAG
To further examine consequences of the mutation on the
biochemical characteristics of MAG, we prepared constructs
that direct the expression of human MAG or human MAG
carrying the S133R mutation (MAG-S133R). In addition, we
cloned human MAG or MAG-S133R upstream of EGFP or
a myc-tag. Western blot analysis of COS7 cells transfected
with the wild-type constructs revealed the presence of mul-
tiple MAG or MAG-GFP glycoforms, whereas MAG or
MAG-GFP containing the S133R mutation appeared as a
single band (Fig. 3A), indicating that the substitution of
serine at position 133 to arginine affected the post-
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Figure 2 Sural nerve biopsy findings in Patient III-2. Paraffin embedded sections stained with haematoxylin and eosin (A), Luxol Fast
blue–periodic acid–Schiff (B), and with immunohistochemical stains for neurofilament (C), MBP (D), S-100 protein (E) and MAG (G), as well as
electron-microscopy (F and H) did not reveal remarkable alterations, except for rare ill-formed onion-bulb structures, noted only on S-100
stained section (E, inset, arrow) and electron-microscopy (F, H, encircled). Myelin sheath of the affected nerve appears relatively thin (F, black
arrow) as opposed to myelin sheath of most axons (F, white arrow). Possible minimal loss of axon-glia interaction (H, asterisks) was noted in rare
myelinated axons, but traction/tearing artefact cannot be excluded. There was complete absence of myelin sheath staining for MAG (G),
compared to a normal control (G, inset). SC = Schwann cell nucleus; ax = axon.
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translational processing of MAG. Further analysis using
endoglycosidase H (EndoH) revealed that while the wild-
type protein contained highly processed complex
oligosaccharides, MAG-S133R only contained immature
asparagine-linked mannose-rich oligosaccharides (Fig. 3B).
The presence of high mannose glycans in glycoproteins is
an indication of endoplasmic reticulum retention and protein
folding abnormalities (Helenius and Aebi, 2004).
Immunolabelling of COS7 cells transfected with wild-type
or mutant MAG using four different antibodies to MAG
revealed that in contrast to monoclonal antibody (Mab)
D3A2G5, which is directed to the extracellular portion of
human MAG (Burger et al., 1990), or polyclonal antibodies
against the intracellular domain (Heape et al., 1999), MAb
513 did not detect the mutant MAG-S133R (Fig. 3C). Given
that the latter antibody recognizes a conformational epitope
(Meyer-Franke et al., 1995), these results further support the
detrimental effect of the S133R mutation on folding of
MAG. These results are in line with previous observations
that N-linked glycosylation of MAG plays a role in its
proper folding (Tropak et al., 1997).
MAG-S133R mutant is trapped
in the endoplasmic reticulum
Whereas wild-type transfected COS7 cells showed
MAG present on the entire cell, MAG-S133R mutant was
concentrated around the nucleus, suggesting that it does
not reach the cell surface (Fig. 3C). To further determine
whether this is the case, we immunolabelled live transfected
COS7 cells using the MAb D3A2G5 (Fig. 4A). Unlike wild-
type MAG, which was detected on the cell surface, MAG-
S133R could only be detected in detergent-permeabilized
cells. Similar distribution was detected in Schwann cells
expressing MAG-GFP and MAG-S133R-GFP (Fig. 4B).
Analysis of Schwann cells co-expressing MAG-MYC or
MAG-S133R-MYC with farnesylated GFP that marks the
plasma membrane (Rhee et al., 2006) showed similar dis-
tribution (Fig. 4C). In addition, cell surface biotinylation of
HEK293T cells expressing MAG-GFP and MAG-S133R-
GFP using a membrane-impermeable reagent demonstrated
that only wild-type MAG was detectable on the cell surface
Figure 3 Characterization of the MAG-S133R mutant. (A) Expression of the wild-type (WT) and mutant (S133R) human MAG (hMAG)
and of these proteins fused to GFP (MAG-GFP) in HEK-293 cells. Western blot analysis was done on total cell lysates using antibodies to MAG or
GFP. The location of molecular weight markers is shown in kDa on the right. (B) MAG-S133R mutant lacks complex glycans. Immunocomplexes
of wild-type (WT) and mutant (S133R) MAG-GFP expressed in HEK-293 cells were left untreated or treated with endoglycosidase H (EndoH),
which cleaves asparagine-linked mannose rich oligosaccharides but not highly processed complex oligosaccharides from glycoproteins. Western
blot analysis was done using an antibody to GFP. Arrowheads mark the location of MAG containing high complex oligosaccharides (a), mannose
rich oligosaccharides (b) and the deglycosylated protein (containing only the core N-acetylglucosamines) (c). The location of molecular weight
markers is shown in kDa on the right. (C) Differential recognition of the MAG-S133R mutant by specific antibodies. Fixed and permeabilized
COS7 cells expressing the wild-type (WT) and mutant (S133R) forms of MAG were immunolabelled using the indicated antibodies. Note that MAb
513 does not recognize the mutant protein. Scale bars = 20 mm.
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(Fig. 4D). Double immunolabelling of HeLa cells express-
ing wild-type or MAG-S133R using antibodies to MAG
and to endoplasmic reticulum protein calnexin (encoded
by CANX) (Ou et al., 1993) or to the Golgi-associated
protein p115 (encoded by USO1) (Waters et al., 1992)
showed that MAG-S133R is conﬁned to the endoplasmic
reticulum but does not co-localized with p115 (Fig. 5A and
B). The mutant, but not the wild-type protein, co-localized
with the endoplasmic reticulum protein vesicle-associated
membrane protein-associated protein B/C (encoded by
VAPB) (Peretti et al., 2008) in both transfected COS7
(Fig. 5C) and rat Schwann cells (Fig. 5F). MAG-S133R
also co-localized with CASPR, contactin-associated protein
(encoded by CNTNAP1) (Fig. 5D), a transmembrane pro-
tein that requires the presence of contactin to exit the endo-
plasmic reticulum (Faivre-Sarrailh et al., 2000; Gollan
et al., 2003). In addition, we found that when expressed
in rat oligodendrocytes, MAG-S133R-GFP was also con-
ﬁned to the endoplasmic reticulum (Fig. 5E).
Immunoprecipitation of MAG-GFP and MAG-S133R-GFP
from HEK293T cells revealed that unlike MAG, MAG-
S133R co-immunoprecipitated with endoplasmic reticu-
lum-resident glycan calnexin and endoplasmic reticulum
chaperone 78 kDa glucose-regulated protein (Bip, encoded
by HSPA5) (Gething, 1999) (Fig. 5G). These results dem-
onstrate that MAG-S133R does not reach the cell surface
and is stuck in the endoplasmic reticulum, further conﬁrm-
ing the detrimental effect of the p.S133R mutation on the
folding and processing of MAG.
MAG-S133R undergoes
proteasome-dependent degradation
Endoplasmic reticulum accumulation of terminally mis-
folded proteins leads to their degradation (Meusser et al.,
2005). To examine whether endoplasmic reticulum-retained
MAG-S133R is subject to degradation, we determined the
half-life of MAG-MYC and MAG-S133R-MYC proteins in
HEK293T cells using cyclohexamide chase assay (Fig. 6A
and B). MAG-S133R-MYC displayed signiﬁcantly higher
Figure 4 MAG-S133R does not reach the cell surface. (A) Cell surface expression of the wild-type (WT) and MAG-S133R (S133R)
proteins in transfected COS7 cells. Cells were stained with the D3A2G5 antibody, which recognize the extracellular region of MAG, either
without (-Tx100) or with ( + Tx100) fixation and permeabilization. The cellular nuclei were labelled with DAPI (blue). (B) Distribution of MAG-
GFP or MAG-S133R-GFP in transfected rat Schwann cells. (C) Distribution of MAG-MYC or MAG-S133-MYC co-infected with plasma membrane
marker farnesylated GFP (FarGFP) in rat Schwann cells. Scale bars: A–C = 20mm. (D) Cell surface expression of MAG-GFP and MAG-S133R-GFP
proteins in MAG-GFP or MAG-S133R-GFP expressing HEK 293T cells. Surface proteins where labelled using impermeable NHS-sulfo biotin.
Lysates were precipitated with streptavidin-conjugated agarose beads followed western blot analysis using antibodies to GFP. The location of
molecular weight markers is shown in kDa on the right.
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degradation rate with a half-life of 2 h compared to a
very stable MAG-MYC. Degradation rate of MAG-S133R
was reduced by the addition of proteasome inhibitor
bortezomib (Fig. 6C). In bortezomib-treated cells, MAG-
S133R-GFP, but not MAG-GFP, was polyubiquitinated,
indicating that it is destined to the proteasome
for degradation (Fig. 6E). In addition, the fact that
polyubiquitination of MAG-S133R-GFP could only be de-
tected after proteasomal inhibition, further indicates that
the mutant protein is rapidly degraded (Altier et al.,
2011). Immunoprecipitation of MAG-GFP and MAG-
S133R-GFP in HEK293T cells showed that as opposed to
wild-type protein, MAG-S133R was associated with com-
ponents of the endoplasmic reticulum-associated protein
degradation (ERAD) machinery, such as P97 (OS9, SEL1)
(Christianson et al., 2008) (Fig. 6D).
To determine what intracellular proteins are associated
with the wild-type and the mutant protein, we subjected
MAG-GFP and MAG-S133R-GFP immunocomplexes to
high resolution mass spectrometry-based proteomic ana-
lysis. Statistical tests showed clear differences between inter-
actors of wild-type MAG-GFP and MAG-S133R-GFP
(Student t-test, FDR = 0.05, S0 = 1.5). Wild-type MAG
was mainly associated with proteins related to the Golgi
apparatus and protein glycosylation, consistent with its
localization at the plasma membrane and its post-
translational N-glycosylation modiﬁcations (Fig. 7). In
contrast, MAG-S133R was associated with a number of
endoplasmic reticulum processing proteins, such as BiP,
calnexin, calreticulin, PDIA3, and PDIA4, with proteins
related to protein folding, such as the chaperonin-contain-
ing T-complex (Horwich and Willison, 1993), and with
COP1 coating proteins, responsible for the retrograde
transport from Golgi back to the endoplasmic reticulum
(Spang and Schekman, 1998) (Fig. 7A and B). Finally,
the mutant protein was associated with a number of
ERAD proteins, such as P97, OS9, SEL1 and EDEM3, as
well as with proteasomal proteins, such as PSMC1,
PSMC4, PSMD1 and PSMD3 (Fig. 7B). Collectively, our
results demonstrate that the p.S133R mutation affects the
post-translational processing and folding of MAG, leading
to its retention in the endoplasmic reticulum with subse-
quent ERAD-mediated proteasomal degradation.
Based on these results, we immunohistochemically
stained sural nerve biopsy sample of Patient III-2 for
MAG showing complete absence of myelin sheath staining
(Fig. 2G).
Discussion
Using genetic linkage, exome sequencing and cellular ex-
pression studies, we identiﬁed a homozygous missense
c.399C4G; p.S133R mutation in MAG in a consanguin-
eous multiplex family with PMD-like disorder. Affected sib-
lings presented the typical for PMD developmental and
motor delay of infantile-onset with early nystagmus and
hypotonia slowly evolving into a form of complicated
Figure 5 S133R MAG accumulates in the endoplasmic reticulum. (A and B) Hela cells expressing the wild-type (WT) or MAG-S133R
(S133R) proteins were immunolabelled using an antibody to MAG and to calnexin (A), or to p115 (B). (C and D) COS7 cells expressing the wild-
type (WT) or MAG-S133R (S133R) proteins were immunolabelled using an antibody to MAG and to the endoplasmic reticulum marker proteins
VAPB (C) or Caspr (D). (E) Rat oligodendrocytes expressing MAG-GFP (WT) or MAG-S133R-GFP (S133R) were immunolabelled using an
antibody to VAPB. (F) Rat Schwann cells expressing MAG-GFP (WT) or MAG-S133R-GFP (S133R) were immunolabelled using an antibody to
VAPB. The GFP fluorescence is shown in green. Note that MAG-S133R is associated with endoplasmic reticulum markers. Scale bars = 20 mm.
(G) MAG-S133R co-imunoprecipitation with endoplasmic reticulum proteins calnexin and BiP. HEK 293Texpressing MAG-GFP and MAG-S133R-
GFP where imunopercipitated using GFP antibody-conjugated beads and subjected to western blot analysis using antibodies to calnexin and BiP.
The location of molecular weight markers is shown in kDa on the right.
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HSP with mental retardation, dysarthria, optic atrophy and
peripheral neuropathy in adulthood. The mild variability
observed among the siblings likely results from age-related
progression of the underlying process. Although HLD1,
HLD2 and HLD4 also exhibit PMD-like and HSP pheno-
types, the combination of clinical and imaging ﬁndings
clearly distinguishes the disorder in this family from other
forms (Supplementary Table 2).
As the PMD-like phenotype is associated with myelin-
related genes PLP1 and GJC2 (Pouwels et al., 2014), in-
volvement of MAG in this family may not be surprising.
The encoded protein MAG is a quantitatively minor
Figure 6 MAG-S133R undergoes proteasome dependent degradation and associates with ERAD machinery. (A and B) MAG-
S133R degradation rate is higher than wild-type MAG. HEK293T expressing wild-type MAG-MYC and MAG-S133-MYC subjected to cyclohex-
amide chase, at the indicated time points, total protein lysates were subjected to western blot analysis using MYC antibody. (B) Degradation rate
plot analysis, MAG intensity relative to actin (image-lab software) from three independent experiments. (C) MAG-S133R degradation is prote-
asome dependent. HEK293T expressing wild-type MAG-MYC and MAG-S133-MYC subjected to cyclohexamide chase with or without borte-
zomib at the indicated time points, total protein lysates were subjected to western blot analysis using MYC antibody. (D and E) MAG-S133R
associates with ERAD protein P97 and is polyubiquitinated. HEK293T expressing MAG-GFP and MAG-S133R-GFP where immunoprecipitation
using GFP antibody conjugated beads and subjected to western blot analysis using P97 and FK-2 antibodies. The location of molecular weight
markers is shown in kDa on the right.
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Figure 7 Mass spectrometry-based interaction proteomics. MAG and MAG-S133R associate with distinct protein interaction networks.
(A) Hierarchical clustering of 423 significantly changing proteins between wild-type and mutant (Student t-test; FDR = 0.05; S0 = 1.5). Selected
enriched categories (GOCC, GOBP and KEGG) based on Fisher exact test are shown on the right, followed by their FDR corrected q-value.
(B) Interaction network of potential interaction partners of MAG wild-type (lower map) and MAG-S133R (upper map). The protein network was
built using the string database. Colours are based on selected significantly enriched categories. MAG is at the centre of each map.
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component of myelin and is expressed solely by oligo-
dendrocytes and Schwann cells (Quarles, 2007), consistent
with the combined CNS and PNS involvement in our pa-
tients. It is an adhesion molecule in the periaxonal layer of
mature non-compact myelin membrane facing the axon.
Based on its location and the fact that its expression cor-
relates with the initiation of myelination (Quarles, 2007),
MAG is thought to mediate interactions between myelinat-
ing glia and their underlying axons (Lopez, 2014).
MAG is a highly glycosylated transmembrane protein con-
taining an extracellular segment with ﬁve tandem Ig-like do-
mains (Quarles, 2007). The c.399C4G mutation identiﬁed
in this family involves the ﬁrst Ig-like domain and leads to a
single amino acid substitution p.S133R, predicted to desta-
bilize the protein, affect its glycosylation and cause defective
folding. Accordingly, our studies demonstrate that the
MAG-S133R mutant contains mannose-rich oligosaccharides
instead of highly processed complex oligosaccharides, indi-
cative of its endoplasmic reticulum retention (Helenius and
Aebi, 2004). In line with the notion that N-linked glycosyla-
tion is important for proper folding (Tropak et al., 1997),
MAG-S133R is not recognized by MAb 513, which recog-
nizes conformational epitope (Meyer-Franke et al., 1995) of
the wild-type protein. The MAG-S133R mutant is present in
the endoplasmic reticulum in a variety of transfected cells,
co-immunoprecipitating with the endoplasmic reticulum
chaperones calnexin and calreticulin, known to increase
the efﬁciency of glycoprotein folding and to ensure that mis-
folded proteins are retained in the endoplasmic reticulum
(Rajagopalan et al., 1994). The mutant MAG also associates
with the endoplasmic reticulum protein BiP (GRP78), which
facilitates protein folding and regulates the unfolded protein
response. Mass spectrometry-based proteomics corroborates
our ﬁndings that MAG-S133R is retained in the endoplasmic
reticulum. Furthermore, MAG-S133R interacts with proteins
of the COP1 family, responsible for the retrograde transport
of proteins from Golgi to endoplasmic reticulum, which
likely prevents mutated MAG to proceed along the secretory
pathway.
Cyclohexamide experiments reveal that MAG-S133R
undergoes rapid degradation and removal, compared to
the stable wild-type MAG. Moreover, this rapid degradation
is proteasome-dependent. Consistent with this observation,
MAG-S133R, but not the wild-type MAG, is polyubiquiti-
nated and is associated with ERAD machinery proteins P97,
OS9, SEL1 and EDEM3. Moreover, MAG-S133R directly
associates with proteasomal subunits representative of the
proteasome-dependent nature of degradation. It is also im-
portant to note that MAG-S133R does not induce the acti-
vation of endoplasmic reticulum stress mediators PERK,
IRE1 and ATF6 endoplasmic reticulum. Collectively, our re-
sults suggest that the c.399C4G; p.S133R mutation in
MAG leads to ERAD-mediated loss of the protein, which
corresponds to the immunohistochemical absence of MAG
in the sural nerve biopsy specimen of Patient III-2 (Fig. 2G).
Loss of tissue immmunoreactivity for MAG also charac-
terizes genetically manipulated knockout mice (Li et al.,
1994; Montag et al., 1994). When examined by the age
of 4 months, affected animals show surprisingly mild clin-
ical and pathological alterations in the CNS and PNS, dis-
play normal peripheral nerve conduction, and are able to
generate mature myelin. Delayed CNS myelination, redun-
dant or disrupted compact myelin, oligodendroglial periax-
onal area and cytoplasmic collar changes (Montag et al.,
1994), tremor and impaired coordination (Li et al., 1994)
are among the reported alterations at this stage (Lopez,
2014). Normal MRI myelination pattern in our patients
in childhood (Patient III-2) and in adulthood is consistent
with these ﬁndings and still leaves a possibility of delayed
myelination in infancy to explain their early PMD-like
manifestations.
At a later age, additional alterations are described in
MAG knockout animals, including degeneration of axons
and myelin in the PNS accompanied by the formation
of onion bulb-like structures (Fruttiger et al., 1995).
Peripheral nerve conduction studies show reduced velocities
with a less signiﬁcantly decreased compound muscle action
potential amplitudes (Weiss et al., 2001). These abnormal-
ities qualitatively resemble electron microscopic ﬁndings in
Patient III-2 (Fig. 2) and an apparent age-related worsening
of the peripheral nerve conduction ﬁndings between sib-
lings, Patients III-5, III-3 and III-2 (Supplementary Table 1).
Long-term alterations in the CNS in MAG knockout ani-
mals include axonal degeneration (Nguyen et al., 2009) and
dying-back oligodendrogliopathy, which possibly represents
initial stages of a slow demyelinating process (Lassmann
et al., 1997). Clinical and electrophysiological signs of the
CNS involvement in our patients in adulthood accompanied
by the cerebral MRI and 1H-magnetic resonance spectros-
copy abnormalities (Supplementary Table 1 and Fig. 1E) are
also indicative of a demyelinating form of leukodystrophy.
Taken together, our ﬁndings conﬁrm a slowly progressive
involvement of the PNS and CNS in this family with
c.399C4G mutation in MAG and are consistent with the
suggested function of MAG in a long-term maintenance and
integrity of myelin and axons (Lopez, 2014).
Recently, another mutation in MAG has been reported in
a monumental study of multiple HSP families (Novarino
et al., 2014). The two affected sisters carrying the
c.1288T4G; p.C430G mutation in the core of the ﬁfth Ig-
like domain, manifested early-onset HSP associated with nys-
tagmus, cerebellar signs, amyotrophy, sensory loss and poor
school achievements, akin to the late clinical phenotype in
our patients. Although their MRI was tabulated as normal,
no details, 1H-magnetic resonance spectroscopy or nerve
conduction results were available for comparison.
In summary, we provide the ﬁrst conclusive evidence for
the involvement of MAG in a combined CNS and PNS
disorder manifesting early PMD-like clinical phenotype
later evolving into a complicated HSP. Given autosomal
recessive inheritance in this family, we postulate that the
underlying mechanism of the p.S133R mutation is related
to the ERAD-mediated loss of MAG function. Because
MAG is developmentally regulated through alternative
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mRNA splicing of the cytoplasmic domain generating short
and long isoforms differentially expressed in the PNS and
CNS, it is conceivable that MAG is responsible for a
broader range of neurogenetic disorders.
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